Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16998545 | 0.97 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL16998542 | 0.91 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL16903743 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL15566227 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL18649663 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL26848566 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL18034003 | 0.90 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL12722376 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL16998550 | 0.87 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1KMT2ANPC1 | |
| SCHEMBL16998543 | 0.87 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364273-A1 | AGENT FOR DETECTING INTERACTION BETWEEN TISSUES AND ORGANS | HAMAMATSU PHOTONICS K.K. (JP) | 2023-11-16 | — | — | US | disclosed |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-9919064-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9713651-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170202984-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9555138-B2 | — | — | 2017-01-31 | — | — | US | disclosed |
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196672-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | SMN1; SMN2 420/4885LMNA 1473/4885MEN1 57/4885 |
| US-20170151353-A9 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | TNNI3, FABP3, TNNT2 | SMN1; SMN2 420/4885LMNA 1473/4885MEN1 57/4885 |
| US-20230364273-A1 | AGENT FOR DETECTING INTERACTION BETWEEN TISSUES AND ORGANS | NOC2L, TNNI3, TNNC1 | SMN1; SMN2 1545/4885LMNA 2892/4885MEN1 194/4885 |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | SMN1; SMN2 699/4885LMNA 1449/4885MEN1 77/4885 |
| US-20170202984-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | SMN1; SMN2 699/4885LMNA 1449/4885MEN1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.